TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04888273

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transition Intervention
Description: Each adolescent-parent pair will be invited to complete 5 components of the intervention (peer support session, parent education session, transition meeting with healthcare providers, family doctor contact, and reading a transition navigation guide) over a 3-month period. These intervention components were designed with the intention of making the transition process transparent for the duo, preparing the adolescent to take responsibility of their own health as it relates to their disorder, and helping the parent step back from the process to help the adolescent integrate to adult care better.
Study: NCT05504733

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Layperson Audiovisual Assist Tourniquet (LAVA TQ)
Description: The Layperson Audiovisual Assist Tourniquet is a hemorrhage control device designed to occlude blood flow in the event of limb hemorrhage. This device provides audiovisual instructions and feedback.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Layperson Audiovisual Assist Tourniquet (LAVA TQ)
Description: The Layperson Audiovisual Assist Tourniquet is a hemorrhage control device designed to occlude blood flow in the event of limb hemorrhage. This device provides audiovisual instructions and feedback.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Combat Application Tourniquet
Description: The Combat Application Tourniquet (CAT) is a hemorrhage control device designed to occlude blood blow in the event of a limb hemorrhage. The CAT utilizes a windlass rod design.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combat Application Tourniquet
Description: The Combat Application Tourniquet (CAT) is a hemorrhage control device designed to occlude blood blow in the event of a limb hemorrhage. The CAT utilizes a windlass rod design.
Study: NCT05852535

Intervention type: PROCEDURE
Intervention: Exploration
Description: abdominal exploration
Study: NCT05346705

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: New individualized upper airway muscle functional training
Description: The two groups of experimental groups were respectively performed tongue/soft palate muscle group control function training and soft palate muscle group vocal resistance training for 7 days.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: New individualized upper airway muscle functional training
Description: The two groups of experimental groups were respectively performed tongue/soft palate muscle group control function training and soft palate muscle group vocal resistance training for 7 days.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: New individualized upper airway muscle functional training
Description: The two groups of experimental groups were respectively performed tongue/soft palate muscle group control function training and soft palate muscle group vocal resistance training for 7 days.
Study: NCT05070767

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurolens spectacle lens
Description: spectacle lens

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo spectacle lens
Description: spectacle lens for refractive error correction
Study: NCT04755361

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Housing Outreach Project Collaboration (HOP-C)
Description: HOP-C has several components: HOP-C Case management is outreach-based (emphasizing community and home contacts) and participant goal-driven, providing coaching and skill building in key functional domains and assistance with navigating various systems (justice, housing, employment, health, education). The mental health component has two parts. One is a weekly, 90-minute, mental health and wellness-oriented group. The group acts, for most, as a stepped care approach, with members moving on to access individual psychotherapy as needed. Peer support is provided by youth with a history of lived experience of homelessness who have successfully achieved housing stability and progress in major life domains. Peers receive extensive training and are formally hired into these roles with their being 2-3 peers on the team.
Study: NCT05555537

Intervention type: DIAGNOSTIC_TEST
Intervention: MiRNA223 and High mobility group box1(HMGB1)
Description: Measure tye 2 biomarkers miRNA223 and HMGB1 in drug resistant and in medically controled epilepsy

Intervention type: DIAGNOSTIC_TEST
Intervention: MiRNA223 and High mobility group box1(HMGB1)
Description: Measure tye 2 biomarkers miRNA223 and HMGB1 in drug resistant and in medically controled epilepsy
Study: NCT04996121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XZP-5955 tablets
Description: Phase I dose escalation:~For each dose cohort, XZP-5955 tablet will be administered orally, single dose for day 1 and then from day 4, administered for continuous cycles of 21 consecutive days for each cycle~Phase I dose expansion:~XZP-5955 tablet will be administered orally, once daily for continuous cycles of 21 consecutive days for each cycle. Some patients for PK sample collection, the drug will be administered single dose for day 1, then from day 4, administered for continuous cycles of 21 consecutive days for each cycle~Phase II:~XZP-5955 tablet will be administered orally, once daily for continuous cycles of 21 consecutive days for each cycle
Study: NCT04246879

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: Subjects undergo one additional delayed MRI sequence
Study: NCT05320471

Intervention type: OTHER
Intervention: This is an observational study
Description: This is an observational study
Study: NCT05782621

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupoint focused ultrasound
Description: An ultrasound beam is normally pulsed in the ratio of 1:5. For perfect transmission of power from the treatment head to the body, the head will be applied perpendicularly to the skin surface. A stationary technique pulsed ultrasound (1 w/cm2) will be used. The application will be two minutes for each acupuncture point and the head will be glided to the next point in the same side; then to the other side for no more than 10 points, then the device will be turned off

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laserpuncture
Description: The laser tip (0.03 cm2 of beam area) will be positioned with the probe head directly on the acupuncture point, in a perpendicular position and in direct contact with the skin, and every point will be treated for 2 min, totaling 16 min of treatment, plus 4 min of rest, to standardize with the traditional acupuncture time, which is 20 min

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional treatment
Description: the patients will receive selective neck strengthening ex for (extension, flexion, sidebending, lateral rotation) and selective neck stretching ex for (extension, flexion, sidebending, lateral rotation)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional treatment
Description: the patients will receive selective neck strengthening ex for (extension, flexion, sidebending, lateral rotation) and selective neck stretching ex for (extension, flexion, sidebending, lateral rotation)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional treatment
Description: the patients will receive selective neck strengthening ex for (extension, flexion, sidebending, lateral rotation) and selective neck stretching ex for (extension, flexion, sidebending, lateral rotation)
Study: NCT05880446

Intervention type: OTHER
Group type: OTHER
Intervention: Bowel symptoms & QoL assessment
Description: QoL and bowel symptoms questionnaires will be held to patients, anthropomorphic measurement, handgrip test, physical activity level and usual diet quality of the patient will be assessed.
Study: NCT05850221

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: weight training
Description: weight training
Study: NCT04739046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Theragene arm
Description: Theragene®,Ad5-yCD/ mutTKSR39rep-ADP with radiation therapy
Study: NCT04760561

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prone position group
Description: Patients randomized to this arm will receive self-prone positioning. Each patient in the intervention group will be helped into the prone position and encouraged to stay in the prone position as long as tolerated (at least 1 hour). The prone positioning consists of placing the patient on his or her stomach with the head on the side. Self-prone position will be performed 45 minutes up to 1 hour after meals to avoid gastrointestinal side effects. The patient will be maintained in prone position until the patient becomes too tired and uncomfortable to keep that position. If patients will asked to regain the supine position before the 1 hour period was complete, patient's prone position will be considered unfeasible and the reason will be reported. Patients who required invasive mechanical ventilation at any time point will be intubated and excluded from the study.
Study: NCT05700162

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Photograph
Description: As soon as she starts to express her milk from the mother, on whatsapp will be asked to look at the photo of the baby sent to her for 5 minutes. She will be asked to express both breasts for 15 minutes every 3 hours.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video
Description: As soon as the mother starts to express her milk, she will be asked to watch the 5-minute video of her baby sent to her on WhatsApp. She will be asked to express both breasts for 15 minutes every 3 hours.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Live Broadcast
Description: As soon as the mother starts to express her milk, she will be asked to watch the 5-minute live video of her baby with the call sent to her from WhatsApp. She will be asked to express both breasts for 15 minutes every 3 hours.
Study: NCT06079970

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neelde Based Confocal Laser Endomicroscopy
Description: Confocal microscopy through the TBNA needle before tissue sampling using the Cellvizio system and AQ flex probe (Mauna Kea Technologies)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional diagnostic bronchoscopy
Description: Conventional diagnostic bronchoscopy with r-EBUS and optionally fluoroscopy AND/OR EMN AND/OR VB AND/OR ultrathin scope

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional diagnostic bronchoscopy
Description: Conventional diagnostic bronchoscopy with r-EBUS and optionally fluoroscopy AND/OR EMN AND/OR VB AND/OR ultrathin scope
Study: NCT05069272

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bakuchiol and Ethyl Linoleate
Description: A synergistic combination of Bakuchiol and Ethyl Linoleate

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: No actives
Study: NCT05700162

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control Group
Description: She will be asked to express both breasts for 15 minutes every 3 hours. No additional action will be taken.
Study: NCT05301114

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Worker support
Description: Participant will receive weekly or monthly support (via phone or in person) from a community health worker. The community health worker will be responsible for continuously assessing the patient's social needs, providing referrals to community based organizations, and assisting with the patient's non-medical needs as they progress through survivorship (e.g. social support, referrals, etc). Individuals who identify no risk factor will receive monthly phone calls, while individuals who identify 1-3 risk factors will receive monthly home visits with interim phone calls for 6 months. Those who identify 4 or more risk factors or have intensive needs such as behavioral health will receive the same services as the medium risk group and will also be connected with the social work teams within each institution.
Study: NCT05255809

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alexander Technique + Routine Physical Therapy
Description: Verbal Instructions in Trunk stabilizing exercises. The time duration will be 15 minutes. Verbal instructions in Stance Phase Time duration 15 minutes.Ankle Strategy. 40 minutes with rest of 5 minutes after 10 minutes. Lessons would be two days a week for 16 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Physical Therapy
Description: Trunk stabilising exercises time duration will be 15 minutes. Stance Phase time duration will be 15 minutes. Ankle Strategy. 40 minutes with rest of 5 minutes after 10 minutes. Two days a week for 16 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Routine Physical Therapy
Description: Trunk stabilising exercises time duration will be 15 minutes. Stance Phase time duration will be 15 minutes. Ankle Strategy. 40 minutes with rest of 5 minutes after 10 minutes. Two days a week for 16 weeks.
Study: NCT06216639

Intervention type: DRUG
Intervention: Bismuth Subcitrate
Description: Tripotassium dicitratobismuthate 120 mg film-coated tablets. Prescribed for both primary and (potential) secondary treatment with bismuth-based quadruple therapy in participants with active H. pylori infection. The prescribed daily dose is 120 mg QID for a period of 14 days.

Intervention type: DRUG
Intervention: Esomeprazole
Description: Esomeprazol 40 mg gastro-resistant tablets or hard capsules. Which one of the three brands is prescribed for an individual participant in this prospective study depends on the decision of a chosen personal physician. Prescribed for both primary and (potential) secondary treatment with bismuth-based quadruple therapy in participants with active H. pylori infection. The prescribed daily dose is 40 mg BID for a period of 14 days.

Intervention type: DRUG
Intervention: Metronidazole
Description: Metronidazol 400 mg tablets. Prescribed for both primary and (potential) secondary treatment with bismuth-based quadruple therapy in participants with active H. pylori infection. The prescribed daily dose is 400 mg QID for a period of 14 days.

Intervention type: DRUG
Intervention: Amoxicillin
Description: Amoxicillin 500 mg dispersible tablets or hard capsules. Which one of the two brands is prescribed for an individual participant in this prospective study depends on the decision of a chosen personal physician. Prescribed only for the primary treatment with bismuth-based quadruple therapy in participants with active H. pylori infection who are not allergic to penicillin. The prescribed daily dose is 500 mg QID for a period of 14 days.

Intervention type: DRUG
Intervention: Clarithromycin
Description: Clarithromycin 500 mg film-coated tablets. Prescribed only for the primary treatment with bismuth-based quadruple therapy in participants with active H. pylori infection who are allergic to penicillin. The prescribed daily dose is 500 mg BID for a period of 14 days.

Intervention type: DRUG
Intervention: Levofloxacin
Description: Levofloxacin 500 mg film-coated tablets. Prescribed only for the (potential) secondary treatment with bismuth-based quadruple therapy in participants with active H. pylori infection. The prescribed daily dose is 500 mg OID for a period of 14 days.
Study: NCT06103201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized 13C-Pyruvate
Description: Hyperpolarized Pyruvate (13C) Injection, containing spin-polarized (hyperpolarized) \[13C\]pyruvate, is being studied as a diagnostic agent in combination with 13C spectroscopic MR imaging. The aim is to visualize \[13C\]pyruvate and its metabolites and thereby distinguish between anatomical areas with normal vs. abnormal metabolism, which should be useful in diagnosing and characterizing, for example, traumatic brain injury.~Hyperpolarized Pyruvate (13C) Injection and \[13C\]pyruvate are general terms used throughout this brochure, which refer to all 13C labeling patterns, such as \[1- 13C\]pyruvate, \[2- 13C\]pyruvate and \[1,2- 13C\]pyruvate. From biological and safety standpoints, pyruvate with each of the labeling patterns behaves identically in the human body \[Koletzko et al., 1997\].

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized 13C-Pyruvate
Description: Hyperpolarized Pyruvate (13C) Injection, containing spin-polarized (hyperpolarized) \[13C\]pyruvate, is being studied as a diagnostic agent in combination with 13C spectroscopic MR imaging. The aim is to visualize \[13C\]pyruvate and its metabolites and thereby distinguish between anatomical areas with normal vs. abnormal metabolism, which should be useful in diagnosing and characterizing, for example, traumatic brain injury.~Hyperpolarized Pyruvate (13C) Injection and \[13C\]pyruvate are general terms used throughout this brochure, which refer to all 13C labeling patterns, such as \[1- 13C\]pyruvate, \[2- 13C\]pyruvate and \[1,2- 13C\]pyruvate. From biological and safety standpoints, pyruvate with each of the labeling patterns behaves identically in the human body \[Koletzko et al., 1997\].

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized 13C-Pyruvate
Description: Hyperpolarized Pyruvate (13C) Injection, containing spin-polarized (hyperpolarized) \[13C\]pyruvate, is being studied as a diagnostic agent in combination with 13C spectroscopic MR imaging. The aim is to visualize \[13C\]pyruvate and its metabolites and thereby distinguish between anatomical areas with normal vs. abnormal metabolism, which should be useful in diagnosing and characterizing, for example, traumatic brain injury.~Hyperpolarized Pyruvate (13C) Injection and \[13C\]pyruvate are general terms used throughout this brochure, which refer to all 13C labeling patterns, such as \[1- 13C\]pyruvate, \[2- 13C\]pyruvate and \[1,2- 13C\]pyruvate. From biological and safety standpoints, pyruvate with each of the labeling patterns behaves identically in the human body \[Koletzko et al., 1997\].
Study: NCT06220331

Intervention type: DEVICE
Intervention: Intra Ocular Lens
Description: Intensity SL Intra Ocular Lens
Study: NCT06193590

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carevix
Description: Cervical stabilization device that uses vacuum

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tenaculum
Description: standard of care cervical stabilization device
Study: NCT04011358

Intervention type: OTHER
Group type: OTHER
Intervention: Sleeping Monitor
Description: to evaluate obstructive sleep apnea

Intervention type: OTHER
Group type: OTHER
Intervention: Sleeping Monitor
Description: to evaluate obstructive sleep apnea
Study: NCT05139186

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence
Description: Artificial intelligence

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence
Description: Artificial intelligence
Study: NCT06061861

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Financial support for healthy foods and free home delivery
Description: Participants will receive monetary support to spend on healthy food items (e.g., vegetables and fruit) through the Instacart platform for a duration of 6 months and have home delivery and service fees waived for 4 orders per month through the Instacart platform for a duration of 6 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Free home delivery
Description: Participants will have home delivery and service fees waived for 4 orders per month through the Instacart platform for a duration of 6 months.
Study: NCT04829851

Intervention type: DEVICE
Intervention: PROTEIN Mobile App
Description: All recruited user groups will be expected to use the PROTEIN app. During this study the subjects will be asked to visit the lab followed by at least 4 weeks usage of the PROTEIN app and then a final lab visit.

Intervention type: DEVICE
Intervention: PROTEIN Mobile App
Description: All recruited user groups will be expected to use the PROTEIN app. During this study the subjects will be asked to visit the lab followed by at least 4 weeks usage of the PROTEIN app and then a final lab visit.

Intervention type: DEVICE
Intervention: PROTEIN Mobile App
Description: All recruited user groups will be expected to use the PROTEIN app. During this study the subjects will be asked to visit the lab followed by at least 4 weeks usage of the PROTEIN app and then a final lab visit.

Intervention type: DEVICE
Intervention: Expert Dashboard
Description: Health care professionals (HCP) will be contacted via email and will also be invited to either attend the lab or meet with the researchers utilizing Zoom/ Microsoft teams to discuss the usage of the expert dashboard within the PROTEIN application.
Study: NCT05572775

Intervention type: PROCEDURE
Intervention: Quadratus lumborum (QL) block
Description: bilateral anterior subcostal quadratus lumborum block

Intervention type: PROCEDURE
Intervention: Quadratus lumborum (QL) block
Description: bilateral anterior subcostal quadratus lumborum block

Intervention type: PROCEDURE
Intervention: Erector Spinae Plane (ESP) Block
Description: bilateral erector spinae plane block

Intervention type: PROCEDURE
Intervention: Erector Spinae Plane (ESP) Block
Description: bilateral erector spinae plane block
Study: NCT05880342

Intervention type: DRUG
Group type: OTHER
Intervention: Reboxetine Pill
Description: 8 mg

Intervention type: DRUG
Group type: OTHER
Intervention: Reboxetine Pill
Description: 8 mg

Intervention type: DRUG
Group type: OTHER
Intervention: Reboxetine Pill
Description: 8 mg

Intervention type: DRUG
Group type: OTHER
Intervention: Methylphenidate Oral Product
Description: 20 mg

Intervention type: DRUG
Group type: OTHER
Intervention: Methylphenidate Oral Product
Description: 20 mg

Intervention type: DRUG
Group type: OTHER
Intervention: Methylphenidate Oral Product
Description: 20 mg
Study: NCT06046144

Intervention type: DIAGNOSTIC_TEST
Intervention: Fluorescence-Advanced videodermatoscopy
Description: Datas collected : Presence or absence of atypical roundish cell, dendritic cell, atypical nests, points, folliculotropism, blue homogenous zone, regular honeycomb pattern.~Between 10 and 60 images taken by a hand-held camera set directly on the skin lesion, with an oily interface.

Intervention type: DIAGNOSTIC_TEST
Intervention: Reflectance confocal microscopy
Description: Datas collected : Presence or absence of atypical roundish cell, dendritic cell, atypical nests, points, folliculotropism, blue homogenous zone, regular honeycomb pattern.~Between 10 and 60 images taken by a hand-held camera set directly on the skin lesion, with an oily interface.

Intervention type: DIAGNOSTIC_TEST
Intervention: Super-high magnification dermoscopy
Description: Datas collected : Presence or absence of atypical roundish cell, dendritic cell, atypical nests, points, folliculotropism, blue homogenous zone, regular honeycomb pattern.~Between 10 and 60 images taken by a hand-held camera set directly on the skin lesion, with an oily interface.